-
1 week ago | 
theamericanmag.com | Madeleine Johnson
Like a character in Chaucer’s Canterbury Tales, I recently joined a British pilgrimage in “April, when its showers are sweet.”The destination of the pilgrimage was the sites of two World War II prisoner-of-war camps in Germany and Poland, Colditz Castle and Stalag Luft III. For modern Britons, these camps and the deaths of the men who attempted to escape them, seem to hold a mythical power not unlike that of St. Thomas Becket, whose shrine drew Chaucer’s merry band.
-
2 weeks ago | 
360dx.com | Madeleine Johnson
NEW YORK – Japan's Eiken Chemical, perhaps best known in the molecular biology space as the developer of the widely used loop-mediated isothemal nucleic acid amplification technology, has overhauled its executive team and revamped its mid- and long-term business strategies.
-
2 weeks ago | 
360dx.com | Madeleine Johnson
NEW YORK – Executives from Bio-Rad Laboratories said at an investment conference on Wednesday afternoon that while US tariff policy is seemingly changing day by day, the firm expects to see approximately $40 million in tariff-related revenue headwinds this year. On Monday, the firm also alerted its customers in an email to forthcoming tariff surcharges.
-
4 weeks ago | 
genomeweb.com | Madeleine Johnson
NEW YORK – Countable Labs, formerly known as Enumerix, expects its chemistries and benchtop reader will allow researchers to measure single DNA molecules quickly and cheaply. After recently rebranding, the Palo Alto, California-based startup will launch its first product, called Countable PCR, at the American Society of Gene & Cell Therapy meeting next week.
-
1 month ago | 
360dx.com | Madeleine Johnson
Get the full story with 360Dx Premium Only $95 for the first 90 days
-
1 month ago | 
genomeweb.com | Madeleine Johnson
This story has been updated to include comments from a call with investors. NEW YORK – Becton Dickinson plans to use its diverse global business to adapt to reduced research funding support, tariffs, and other headwinds as it continues to suss out buyers for its biosciences and diagnostics business, the firm said on Thursday as it also reported its fiscal second quarter financial results.
-
1 month ago | 
360dx.com | Madeleine Johnson
NEW YORK – Qiagen highlighted its evolving plans to further expand its oncology portfolio at the American Association for Cancer Research meeting this week in Chicago, with plans to debut two new sample prep systems and a next-generation sequencing product developed under an expanded collaboration with Myriad Genetics in the coming year.
-
1 month ago | 
genomeweb.com | Madeleine Johnson
NEW YORK – Baebies brought its multimodal diagnostic system one step closer to clinical use this week with the announcement of breakthrough device designation from the US Food and Drug Administration. As part of a strategic shift, the Durham, North Carolina-based firm recently licensed its digital microfluidic newborn screening business and Seeker platform in order to advance commercialization of its Finder platform and is currently focusing on clinical trials for various assays on that platform.
-
1 month ago | 
360dx.com | Madeleine Johnson
NEW YORK – Baebies brought its multimodal diagnostic system one step closer to clinical use this week with the announcement of breakthrough device designation from the US Food and Drug Administration. As part of a strategic shift, the Durham, North Carolina-based firm recently licensed its digital microfluidic newborn screening business and Seeker platform in order to advance commercialization of its Finder platform and is currently focusing on clinical trials for various assays on that platform.
-
1 month ago | 
360dx.com | Madeleine Johnson
NEW YORK – Researchers at Florida Atlantic University are progressing on a project to create a highly sensitive molecular diagnostic system for HIV self testing. With their recent Phase II funding only slightly delayed by new National Institutes of Health funding policies, the team expects to soon prototype its disposable microfluidic device on clinical samples as part of its path toward commercialization.
